GCTK:NASDAQGlucoTrack, Inc. Analysis

GlucoTrack, Inc. (GCTK) is trading at $0.312, barely above its 30‑day support of $0.291 and well below the 20‑day SMA of $0.455, indicating a steep downtrend. RSI sits at 25.7, suggesting the stock is oversold, yet the MACD histogram remains negative and the signal line is bearish, reinforcing continued downside pressure. Volume is on a decreasing trend and the 30‑day volatility exceeds 148%, while a computed beta of 1.5 points to heightened sensitivity to market swings. The price is far under the 200‑day SMA of $3.22, highlighting a long‑term bearish bias.
Fundamentally, the company reports zero revenue, negative EBITDA of $‑16.7 M, and a cash burn of $‑16.3 M, with a negative book value per share of $‑0.337. Valuation multiples are distorted – a trailing PE of 0.05 versus an industry average of 25.9 and a price‑to‑book of –0.93 – reflecting the severe financial distress. With a max drawdown of –97% and no dividend history, the risk profile is extremely high, especially given the high regulatory hurdles for its implantable glucose monitor.